- Artivion (NYSE:AORT) on Monday said it has amended its credit facility and option purchase agreements with Endospan.
- Through the agreement, Artivion will provide Endospan with $25M of additional debt funding to obtain FDA approval for NEXUS.
- The amendment to the agreement also includes an upfront payment associated with the purchase option to be reduced from $250M to $175M, resulting in an upfront purchase price of $135M, inclusive of loan off-set.
- The amendment also added that the $100M minimum payout for the earnout is eliminated.
- The company does not anticipate the amended agreement with Endospan to have a material impact on its full-year 2024 financial guidance.
- Press release.
Source link
